Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab-Reference-Cited by-同舟云学术

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

Published:2022-01-29 Issue:5 Volume:36 Page:1426-1428
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Abdallah Nadine^ORCID,Murray David^ORCID,Dispenzieri Angela^ORCID,Kapoor Prashant^ORCID,Gertz Morie A.,Lacy Martha Q.,Hayman Suzanne R.,Buadi Francis K.^ORCID,Gonsalves Wilson,Muchtar Eli^ORCID,Leung Nelson^ORCID,Dingli David^ORCID,Kourelis Taxiarchis^ORCID,Warsame Rahma,Binder Moritz^ORCID,Kyle Robert A.,Rajkumar S. Vincent,Kumar Shaji^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01501-0.pdf

Reference14 articles.

1. Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001;25:1–12.

2. Tang F, Malek E, Math S, Schmotzer CL, Beck RC. Interference of therapeutic monoclonal antibodies with routine serum protein electrophoresis and immunofixation in patients with myeloma: frequency and duration of detection of daratumumab and elotuzumab. Am J Clin Pathol. 2018;150:121–9.

3. Milani P, Murray DL, Barnidge DR, Kohlhagen MC, Mills JR, Merlini G, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017;92:772–9.

4. Kohlhagen MC, Barnidge DR, Mills JR, Stoner J, Gurtner KM, Liptac AM, et al. Screening method for M-proteins in serum using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. 2016;62:1345–52.

5. Moore LM, Cho S, Thoren KL. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins. Clin Chim Acta. 2019;492:91–4.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients;Experimental Hematology & Oncology;2024-08-06

2. Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T‐cells;British Journal of Haematology;2024-06-18

3. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab;Leukemia;2024-06-17

4. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM);Clinical Cancer Research;2024-01-03

5. Insight into the mechanism of CD34⁺ cell mobilisation impairment in multiple myeloma patients treated with anti‐CD38 therapy;British Journal of Haematology;2023-10-09